IU is a feasible biomarker with potential benefit not only in the anti-EGFR therapy response assessment for non-small cell lung cancer but also in predicting the radio-chemotherapy outcome for cervical cancer (40, 41). This evidence concerns the gene EGFR and non-small cell lung carcinoma.